XERS
Xeris Biopharma Holdings, Inc. NASDAQ Listed Jun 21, 2018$6.63
Mkt Cap $1.1B
52w Low $4.30
40.3% of range
52w High $10.08
50d MA $5.92
200d MA $7.07
P/E (TTM)
1794.3x
EV/EBITDA
93.3x
P/B
73.6x
Debt/Equity
2.8x
ROE
4.0%
P/FCF
45.1x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$5.92
200d MA
$7.07
Avg Volume
1.8M
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
180 North LaSalle Street · Chicago, IL 60601 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 6.37 | +5.2% | +4.1% | — | — | — | — | — |
| Mar 2, 2026 | AMC | 0.03 | 0.06 | +100.0% | 6.02 | -3.5% | -1.3% | +2.2% | -0.5% | -3.8% | -3.6% | — |
| Nov 6, 2025 | AMC | 0.01 | 0.00 | -65.0% | 7.71 | -2.3% | -3.6% | +3.9% | -3.6% | +2.0% | -4.3% | — |
| Aug 7, 2025 | AMC | -0.03 | -0.01 | +66.7% | 6.60 | +0.8% | +3.6% | +5.3% | +1.4% | -0.3% | +0.3% | — |
| May 8, 2025 | AMC | -0.07 | -0.06 | +14.3% | 5.16 | +0.6% | -2.9% | -1.2% | -1.0% | -5.3% | +3.2% | — |
| Mar 6, 2025 | AMC | -0.08 | -0.03 | +62.5% | 4.13 | -0.2% | +2.7% | +8.3% | -4.4% | +4.1% | -0.2% | — |
| Nov 8, 2024 | AMC | -0.09 | -0.06 | +33.3% | 3.47 | -1.2% | -5.5% | -4.0% | +0.0% | -3.2% | -4.3% | — |
| Aug 8, 2024 | AMC | -0.11 | -0.10 | +9.1% | 2.23 | +0.9% | +4.0% | -3.0% | +12.9% | +0.4% | +2.7% | — |
| May 9, 2024 | AMC | -0.12 | -0.14 | -16.7% | 1.88 | +1.6% | -6.4% | +7.4% | +0.5% | +4.2% | +2.0% | — |
| Mar 6, 2024 | AMC | -0.09 | -0.10 | -11.1% | 2.48 | +2.0% | -1.6% | -3.7% | -4.3% | -1.8% | -1.4% | — |
| Nov 9, 2023 | AMC | -0.12 | -0.09 | +25.0% | 1.80 | +3.6% | -6.6% | -3.9% | -3.7% | -5.8% | +6.8% | — |
| Aug 8, 2023 | AMC | -0.13 | -0.14 | -7.7% | 2.58 | -0.4% | -8.9% | -0.9% | -2.1% | -1.3% | -0.9% | — |
| May 9, 2023 | AMC | -0.17 | -0.12 | +29.4% | 2.73 | +0.0% | +7.3% | -0.3% | -0.7% | -2.1% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.12 | $7.08 | +15.7% | -1.6% | -1.3% | +2.2% | -0.5% | -3.8% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.13 | $8.24 | +1.4% | -2.5% | -0.8% | -2.0% | -1.7% | -2.2% |
| Nov 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $7.71 | $7.53 | -2.3% | -3.6% | +3.9% | -3.6% | +2.0% | -4.3% |
| Nov 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.71 | $7.53 | -2.3% | -3.6% | +3.9% | -3.6% | +2.0% | -4.3% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.71 | $7.53 | -2.3% | -3.6% | +3.9% | -3.6% | +2.0% | -4.3% |
| Oct 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.23 | $9.44 | +2.3% | +4.2% | +0.9% | -0.1% | +2.1% | +0.0% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.52 | +0.7% | +2.7% | +8.2% | -7.0% | +1.8% | +0.6% |
| Aug 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $7.36 | $7.36 | +0.0% | +0.0% | +2.9% | +0.3% | +2.1% | +0.3% |
| Aug 8 | Craig-Hallum | Maintains | Buy → Buy | — | $6.60 | $6.65 | +0.8% | +3.6% | +5.3% | +1.4% | -0.3% | +0.3% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.60 | $6.65 | +0.8% | +3.6% | +5.3% | +1.4% | -0.3% | +0.3% |
| Jun 5 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.43 | $4.45 | +0.5% | +0.7% | +2.7% | -2.2% | +1.6% | -3.7% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.16 | $5.19 | +0.6% | -2.9% | -1.2% | -1.0% | -5.3% | +3.2% |
| Mar 7 | Craig-Hallum | Maintains | Buy → Buy | — | $4.13 | $4.12 | -0.2% | +2.7% | +8.3% | -4.4% | +4.1% | -0.2% |
| Mar 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $4.13 | $4.12 | -0.2% | +2.7% | +8.3% | -4.4% | +4.1% | -0.2% |
| Mar 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.13 | $4.12 | -0.2% | +2.7% | +8.3% | -4.4% | +4.1% | -0.2% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.13 | $4.12 | -0.2% | +2.7% | +8.3% | -4.4% | +4.1% | -0.2% |
| Jan 29 | Jefferies | Maintains | Buy → Buy | — | $3.53 | $3.50 | -0.8% | +3.4% | +0.3% | -2.7% | +0.8% | +1.4% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.47 | $3.43 | -1.2% | -5.5% | -4.0% | +0.0% | -3.2% | -4.3% |
| Nov 11 | Piper Sandler | Downgrade | Overweight → Neutral | — | $3.47 | $3.43 | -1.2% | -5.5% | -4.0% | +0.0% | -3.2% | -4.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.60 | +2.0% | +2.7% | +2.7% | +1.1% | -0.7% | +5.2% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.22 | $2.24 | +0.9% | +1.8% | +8.4% | -5.3% | +4.7% | -2.9% |
| May 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.88 | $1.91 | +1.6% | -6.4% | +7.4% | +0.5% | +4.2% | +2.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.53 | +2.0% | -1.6% | -3.7% | -4.3% | -1.8% | -1.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.67 | -0.9% | -3.9% | -3.7% | -5.8% | +6.8% | +12.7% |
| Nov 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.80 | $1.87 | +3.6% | -6.6% | -3.9% | -3.7% | -5.8% | +6.8% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.58 | $2.57 | -0.4% | -8.9% | -0.9% | -2.1% | -1.3% | -0.9% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.73 | $2.73 | +0.0% | +7.3% | -0.3% | -0.7% | -2.1% | +0.4% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.36 | +0.7% | -7.4% | -3.2% | +0.0% | +7.4% | +0.0% |
| Jan 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.22 | $1.20 | -1.6% | +3.3% | -3.2% | +1.6% | -1.6% | +3.3% |
| Apr 28 | Craig-Hallum | Maintains | Buy → Buy | — | $2.42 | $2.53 | +4.5% | +0.4% | +0.4% | +0.8% | -0.4% | -4.9% |
| Mar 16 | Mizuho | Maintains | Buy → Buy | — | $2.67 | $2.70 | +1.1% | +4.5% | +2.9% | -3.5% | +0.0% | +2.9% |
| Feb 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.57 | $2.51 | -2.3% | +4.3% | -4.9% | -4.3% | -2.5% | -5.9% |
| Dec 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.43 | $2.99 | +23.0% | +20.6% | -4.1% | -7.1% | -3.4% | +4.8% |
| Dec 31 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.43 | $2.99 | +23.0% | +20.6% | -4.1% | -7.1% | -3.4% | +4.8% |
| Nov 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.39 | $2.53 | +5.9% | +2.5% | -2.4% | -5.0% | -4.8% | -3.7% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.86 | +3.3% | +3.3% | +5.9% | -1.5% | +5.7% | -5.4% |
| Apr 23 | Mizuho | Maintains | Buy → Buy | — | $1.67 | $1.69 | +1.2% | +9.6% | +3.3% | +9.0% | +10.2% | +16.7% |
| Feb 20 | Mizuho | Maintains | Buy → Buy | — | $4.71 | $4.66 | -1.1% | -1.5% | -5.6% | -6.4% | -1.2% | -4.9% |
| Feb 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.00 | $4.25 | +6.2% | +8.2% | +8.8% | -1.5% | -5.6% | -6.4% |
| Sep 11 | Mizuho | Maintains | Buy → Buy | — | $9.74 | $9.86 | +1.2% | +4.9% | +1.5% | +0.5% | +5.6% | -2.4% |
| Jul 17 | Mizuho | Maintains | Buy → Buy | — | $18.40 | $18.33 | -0.4% | +4.8% | +1.5% | -2.4% | +9.1% | -3.1% |
| Jul 16 | Jefferies | Maintains | Buy → Buy | — | $18.50 | $18.55 | +0.3% | -0.5% | +4.8% | +1.5% | -2.4% | +9.1% |
| Jul 16 | Leerink Swann | Maintains | Outperform → Outperform | — | $18.50 | $18.55 | +0.3% | -0.5% | +4.8% | +1.5% | -2.4% | +9.1% |
| Jul 16 | RBC Capital | Maintains | Outperform → Outperform | — | $18.50 | $18.55 | +0.3% | -0.5% | +4.8% | +1.5% | -2.4% | +9.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Hecht BethOff | See Remarks | Sell | 16,667 | $6.23 | $104K | 1,193,173 | +0.96% | -1.51% |
8-K · 2.02
!! High
Xeris Biopharma Holdings, Inc. -- 8-K 2.02: Earnings Results
Xeris Biopharma reported quarterly earnings results, with detailed financial performance metrics available in the attached press release exhibit.
May 7
8-K · 5.02
!!! Very High
Xeris Biopharma Holdings, Inc. -- 8-K 5.02: Executive Change
Xeris Biopharma director Jeffrey Sherman's departure reduces board oversight capacity and may signal internal governance changes or strategic disagreements among leadership.
Apr 21
8-K
Xeris Biopharma Holdings, Inc. -- 8-K Filing
Xeris Biopharma achieved record 2025 revenues of $292 million and projects 28-33% growth to $375-390 million in 2026, signaling strong commercial execution and investor confidence in its product portfolio.
Mar 2
8-K · 7.01
! Medium
Xeris Biopharma Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xeris Biopharma filed a Hatch-Waxman patent infringement lawsuit against two ANDA filers in New Jersey federal court, seeking to block generic competition and extend market exclusivity for its products.
Feb 27
Data updated apr 27, 2026 10:29am
· Source: massive.com